KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Assets: 2009-2024

Historic Assets for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $1.2 billion.

  • Acadia Pharmaceuticals' Assets rose 36.23% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 36.23%. This contributed to the annual value of $1.2 billion for FY2024, which is 58.59% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Assets of $1.2 billion as of FY2024, which was up 58.59% from $749.0 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Assets high stood at $1.2 billion for FY2024, and its period low was $587.8 million during FY2022.
  • Its 3-year average for Assets is $841.5 million, with a median of $749.0 million in 2023.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Assets declined by 16.04% in 2022, and later soared by 58.59% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Assets (Yearly) stood at $782.6 million in 2020, then dropped by 10.54% to $700.1 million in 2021, then fell by 16.04% to $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then spiked by 58.59% to $1.2 billion in 2024.